Claims for Patent: 10,479,832

Summary for Patent: 10,479,832

Title:	Method of treating bone disease
Abstract:	The disclosure provides compositions and methods comprising a sialoadhesin binding moiety for treating metabolic and genetic bone disease, especially for treating a bone disorder of hyper-resorption of bone and/or enhanced activation of osteoclasts.
Inventor(s):	Elewaut; Dirk (Heusden, BE), Louagie; Els (Torhout, BE), Juchtmans; Nele (Ghent, BE)
Assignee:	Universiteit Gent (Ghent, BE) VIB VZW (Ghent, BE)
Application Number:	15/129,792
Patent Claims:	1. A pharmaceutical composition comprising: an antibody that specifically binds sialoadhesin (Sn); an agent for treating bone disorders in an amount useful for the treatment of a bone loss disorder or bone loss disorders in the subject; and a pharmaceutically acceptable carrier and/or excipient. 2. The pharmaceutical composition of claim 1, wherein the antibody antagonizes sialoadhesin-mediated osteoclast fusion. 3. The pharmaceutical of claim 1, wherein the agent for treating bone disorders is selected from the group consisting of estrogens, selective estrogen receptor modulators, alendronate, risedronate, calcitonin, parathyroid hormone, Teriparatide, RANKL inhibitors, cathepsin K inhibitors, integrin inhibitors, src inhibitors, V-ATPase inhibitors, bafilomycin; zoledronic acid, clodronate, tiludronate, pamidronate, etidronate, ibandronate, partial estrogen agonists and antagonists, genistein, daidzein and related phytoestrogens, tamoxifen, bone binding transition metals gallium, thallium, and indium, and inhibitors of chloride channel activity. 4. A pharmaceutical composition comprising: an antibody that specifically binds sialoadhesin (Sn); an agent for treating bone disorders; and a pharmaceutically acceptable carrier and/or excipient. 5. The pharmaceutical of claim 4, wherein the agent for treating bone disorders is selected from the group consisting of estrogens, selective estrogen receptor modulators, alendronate, risedronate, calcitonin, parathyroid hormone, Teriparatide, RANKL inhibitors, cathepsin K inhibitors, integrin inhibitors, src inhibitors, V-ATPase inhibitors, bafilomycin; zoledronic acid, clodronate, tiludronate, pamidronate, etidronate, ibandronate, partial estrogen agonists and antagonists, genistein, daidzein and related phytoestrogens, tamoxifen, bone binding transition metals gallium, thallium, and indium, and inhibitors of chloride channel activity.

Details for Patent 10,479,832

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2034-03-31